Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma

Ann Surg Oncol. 2020 May;27(5):1338-1347. doi: 10.1245/s10434-020-08221-2. Epub 2020 Feb 28.

Abstract

This is the second part of a two-part review on pheochromocytoma and paragangliomas (PPGLs). In this part, perioperative management, including preoperative preparation, intraoperative, and postoperative interventions are reviewed. Current data on outcomes following resection are presented, including outcomes after cortical-sparing adrenalectomy for bilateral adrenal disease. In addition, pathological features of malignancy, surveillance considerations, and the management of advanced disease are also discussed.

Publication types

  • Review

MeSH terms

  • Adrenal Gland Neoplasms / complications
  • Adrenal Gland Neoplasms / surgery*
  • Adrenalectomy / methods
  • Adrenergic alpha-Antagonists / therapeutic use
  • Adrenergic beta-Antagonists / therapeutic use
  • Calcium Channel Blockers / therapeutic use
  • Enzyme Inhibitors / therapeutic use
  • Fluid Therapy
  • Humans
  • Hyperinsulinism / diagnosis
  • Hyperinsulinism / epidemiology
  • Hyperinsulinism / therapy
  • Hypertension / drug therapy*
  • Hypertension / etiology
  • Hypoglycemia / diagnosis
  • Hypoglycemia / epidemiology
  • Hypoglycemia / therapy*
  • Hypotension / diagnosis
  • Hypotension / epidemiology
  • Hypotension / therapy*
  • Laparoscopy
  • Multiple Endocrine Neoplasia Type 2a
  • Multiple Endocrine Neoplasia Type 2b
  • Neoplasm Recurrence, Local / epidemiology
  • Paraganglioma / complications
  • Paraganglioma / surgery
  • Paraganglioma, Extra-Adrenal / complications
  • Paraganglioma, Extra-Adrenal / surgery*
  • Perioperative Care / methods*
  • Pheochromocytoma / complications
  • Pheochromocytoma / surgery*
  • Postoperative Complications / diagnosis
  • Postoperative Complications / epidemiology
  • Postoperative Complications / therapy*
  • Robotic Surgical Procedures
  • Treatment Outcome
  • Tyrosine 3-Monooxygenase / antagonists & inhibitors
  • Vasoconstrictor Agents / therapeutic use
  • von Hippel-Lindau Disease

Substances

  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers
  • Enzyme Inhibitors
  • Vasoconstrictor Agents
  • Tyrosine 3-Monooxygenase